Retatrutide Featured in New MASLD Review in Frontiers in Pharmacology

A new publication involving retatrutide was listed on October 13, 2026. The article, titled "From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease," appeared in Frontiers in Pharmacology. The publication is indexed under PubMed ID 42947668. According to the available listing, the article addresses dual and triple agonists, a category that includes retatrutide, in the context of metabolic dysfunction-associated steatotic liver disease, also known as MASLD. No specific findings, results, or conclusions from the publication are detailed in the available event data. The listing confirms only the title, journal, and publication date as facts. Readers interested in the full scope of the discussion, including any data or analysis presented, should consult the original article directly through the source link. This brief does not summarize or interpret the content of the publication beyond what has been confirmed. For more background on retatrutide, including its classification and regulatory status, readers can refer to the compound overview for additional context.